These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19953539)

  • 1. Proteomics profile of cellular response to chiral drugs: prospects for pharmaceutical applications.
    Bun Ching C; Zhang J; Sui J; Ning Chen W
    Proteomics; 2010 Feb; 10(4):888-93. PubMed ID: 19953539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding proteomics into the analysis of chiral drugs.
    Sui J; Zhang J; Ching CB; Chen WN
    Mol Biosyst; 2009 Jun; 5(6):603-8. PubMed ID: 19462017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of LC/MS to proteomics studies: current status and future prospects.
    Chen G; Pramanik BN
    Drug Discov Today; 2009 May; 14(9-10):465-71. PubMed ID: 19429505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of hyphenated LC-MS techniques in pharmaceutical analysis.
    Ermer J; Vogel M
    Biomed Chromatogr; 2000 Oct; 14(6):373-83. PubMed ID: 11002275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chiral purity assay for Flindokalner using tandem mass spectrometry: method development, validation, and benchmarking.
    Young BL; Cooks RG; Madden MC; Bair M; Jia J; Aubry AF; Miller SA
    J Pharm Biomed Anal; 2007 Apr; 43(5):1602-8. PubMed ID: 17298872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chiral liquid chromatography-tandem mass spectrometric methods for stereoisomeric pharmaceutical determinations.
    Chen J; Korfmacher WA; Hsieh Y
    J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Jun; 820(1):1-8. PubMed ID: 15866486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: Recent application of chiral liquid chromatography-tandem mass spectrometric methods for enantiomeric pharmaceutical and biomedical determinations.
    Nie Y; Liu X; Yang X; Zhao Z
    J Chromatogr Sci; 2013 Sep; 51(8):753-63. PubMed ID: 23315149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of liquid chromatography-mass spectrometry for the identification of drug degradation products in pharmaceutical formulations.
    Wu Y
    Biomed Chromatogr; 2000 Oct; 14(6):384-96. PubMed ID: 11002276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an information-rich LC-MS/MS database for the analysis of drugs in postmortem specimens.
    Liu HC; Liu RH; Ho HO; Lin DL
    Anal Chem; 2009 Nov; 81(21):9002-11. PubMed ID: 19788251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LC/MS applications in drug development.
    Lee MS; Kerns EH
    Mass Spectrom Rev; 1999; 18(3-4):187-279. PubMed ID: 10568041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of recent advances in mass spectrometric methods for gas-phase chiral analysis of pharmaceutical and biological compounds.
    Wu L; Vogt FG
    J Pharm Biomed Anal; 2012 Oct; 69():133-47. PubMed ID: 22579598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing reproducibility of a protein dynamics study using in vivo labeling and liquid chromatography tandem mass spectrometry.
    Molina H; Parmigiani G; Pandey A
    Anal Chem; 2005 May; 77(9):2739-44. PubMed ID: 15859588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput chiral liquid chromatography/tandem mass spectrometry.
    Bakhtiar R; Tse FL
    Rapid Commun Mass Spectrom; 2000; 14(13):1128-35. PubMed ID: 10867688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative proteomics profile of osteoblasts cultured on dissimilar hydroxyapatite biomaterials: an iTRAQ-coupled 2-D LC-MS/MS analysis.
    Xu J; Khor KA; Sui J; Zhang J; Tan TL; Chen WN
    Proteomics; 2008 Oct; 8(20):4249-58. PubMed ID: 18924181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomics technology and therapeutics.
    Hong ML; Jiang N; Gopinath S; Chew FT
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):563-8. PubMed ID: 16700895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.
    Katsila T; Siskos AP; Tamvakopoulos C
    Mass Spectrom Rev; 2012; 31(1):110-33. PubMed ID: 21698655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocratic solid phase extraction-liquid chromatography (SPE-LC) interfaced to high-performance tandem mass spectrometry for rapid protein identification.
    Hørning OB; Kjeldsen F; Theodorsen S; Vorm O; Jensen ON
    J Proteome Res; 2008 Aug; 7(8):3159-67. PubMed ID: 18578518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomics and systems biology--how relevant are the developments to veterinary pharmacology, toxicology and therapeutics?
    Witkamp RF
    J Vet Pharmacol Ther; 2005 Jun; 28(3):235-45. PubMed ID: 15953196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.